Maybe not. Why wouldn't institutional selling continue for either rebalancing or restrictions on maintaining an investment on a sub-$5 stock?
On the other hand, the fact there has been no announcement of a generic Dacogen introduction means a full continuation of that revenue stream, providing close to a 100% offset to the cost of ASTX's pipeline drug testing. If SG-110 is perceived by generic drug companies to be an eventual superior replacement to Dacogen, it may not be too profitable to devote the resources to market a generic version now.. .
ahande and dsk0722 had posted it yesterday. I sure am grateful to them; it saved me from wondering if something extraterrestial had happened. I could tell from timehusk's post earlier today that he hadn't read it, so I reposted it. I like the pps bounced from the low of 4.22 to 4.65. Long and strong on the science